GB0706632D0 - New purine derivatives - Google Patents

New purine derivatives

Info

Publication number
GB0706632D0
GB0706632D0 GBGB0706632.7A GB0706632A GB0706632D0 GB 0706632 D0 GB0706632 D0 GB 0706632D0 GB 0706632 A GB0706632 A GB 0706632A GB 0706632 D0 GB0706632 D0 GB 0706632D0
Authority
GB
United Kingdom
Prior art keywords
purine derivatives
new purine
new
derivatives
purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0706632.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Cancer Research Technology Ltd
Original Assignee
Cyclacel Ltd
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd, Cancer Research Technology Ltd filed Critical Cyclacel Ltd
Priority to GBGB0706632.7A priority Critical patent/GB0706632D0/en
Publication of GB0706632D0 publication Critical patent/GB0706632D0/en
Priority to RU2009140753/04A priority patent/RU2461559C2/ru
Priority to BRPI0809996A priority patent/BRPI0809996B8/pt
Priority to EP08718980.9A priority patent/EP2139893B1/en
Priority to JP2010501585A priority patent/JP5466145B2/ja
Priority to PL08718980T priority patent/PL2139893T3/pl
Priority to AU2008235361A priority patent/AU2008235361B2/en
Priority to CN2008800189406A priority patent/CN101679434B/zh
Priority to HK10106563.2A priority patent/HK1139939B/en
Priority to CA2681529A priority patent/CA2681529C/en
Priority to PCT/GB2008/001173 priority patent/WO2008122767A2/en
Priority to ES08718980T priority patent/ES2427845T3/es
Priority to MX2009010660A priority patent/MX2009010660A/es
Priority to US12/573,337 priority patent/US8592581B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
GBGB0706632.7A 2007-04-04 2007-04-04 New purine derivatives Ceased GB0706632D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB0706632.7A GB0706632D0 (en) 2007-04-04 2007-04-04 New purine derivatives
MX2009010660A MX2009010660A (es) 2007-04-04 2008-04-02 Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas.
AU2008235361A AU2008235361B2 (en) 2007-04-04 2008-04-02 2, 6, 9-substituted purine derivatives having anti proliferative properties
HK10106563.2A HK1139939B (en) 2007-04-04 2008-04-02 2,6,9-substituted purine derivatives having antiproliferative properties
EP08718980.9A EP2139893B1 (en) 2007-04-04 2008-04-02 2,6,9-substituted purine derivatives having antiproliferative properties
JP2010501585A JP5466145B2 (ja) 2007-04-04 2008-04-02 抗増殖性を有する２，６，９−置換プリン誘導体
PL08718980T PL2139893T3 (pl) 2007-04-04 2008-04-02 2,6,9-Podstawione pochodne puryny o właściwościach antyproliferacyjnych
RU2009140753/04A RU2461559C2 (ru) 2007-04-04 2008-04-02 Соединения
CN2008800189406A CN101679434B (zh) 2007-04-04 2008-04-02 具有抗增殖性质的2,6,9-取代的嘌呤衍生物
BRPI0809996A BRPI0809996B8 (pt) 2007-04-04 2008-04-02 compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas
CA2681529A CA2681529C (en) 2007-04-04 2008-04-02 2, 6, 9-substituted purine derivatives having anti proliferative properties
PCT/GB2008/001173 WO2008122767A2 (en) 2007-04-04 2008-04-02 2, 6, 9-substituted purine derivatives having anti proliferative properties
ES08718980T ES2427845T3 (es) 2007-04-04 2008-04-02 Derivados de purina 2,6,9-sustituidos que tienen propiedades antiproliferativas
US12/573,337 US8592581B2 (en) 2007-04-04 2009-10-05 Trisubstituted purine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0706632.7A GB0706632D0 (en) 2007-04-04 2007-04-04 New purine derivatives

Publications (1)

Publication Number Publication Date
GB0706632D0 true GB0706632D0 (en) 2007-05-16

Family

ID=38090893

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0706632.7A Ceased GB0706632D0 (en) 2007-04-04 2007-04-04 New purine derivatives

Country Status (13)

Country Link
US (1) US8592581B2 (https=)
EP (1) EP2139893B1 (https=)
JP (1) JP5466145B2 (https=)
CN (1) CN101679434B (https=)
AU (1) AU2008235361B2 (https=)
BR (1) BRPI0809996B8 (https=)
CA (1) CA2681529C (https=)
ES (1) ES2427845T3 (https=)
GB (1) GB0706632D0 (https=)
MX (1) MX2009010660A (https=)
PL (1) PL2139893T3 (https=)
RU (1) RU2461559C2 (https=)
WO (1) WO2008122767A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0903346D0 (en) 2009-02-27 2009-04-08 Cambridge Advanced Tech Transgenic Plants
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
CA2973949C (en) 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
US11340215B2 (en) 2016-02-26 2022-05-24 Japanese Foundation For Cancer Research Screening method of anticancer agent focused on function of HP1 and evaluation system
KR102524773B1 (ko) * 2017-01-26 2023-04-21 싸이클라셀 리미티드 퓨린 유도체의 제조 방법
EP3388432A1 (en) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
CR20210287A (es) 2018-11-01 2022-02-15 Syros Pharmaceuticals Inc Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
RU2754441C2 (ru) * 2019-12-30 2021-09-02 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
GB202000901D0 (en) 2020-01-22 2020-03-04 Cyclacel Ltd Process
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers
US20240247001A1 (en) 2022-12-16 2024-07-25 Astrazeneca Ab 2,6,9-trisubstituted purines
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
HK1044334A1 (zh) * 1999-02-01 2002-10-18 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US20080125404A1 (en) * 2004-08-27 2008-05-29 Cyclacel Limited Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination

Also Published As

Publication number Publication date
CA2681529A1 (en) 2008-10-16
AU2008235361A1 (en) 2008-10-16
JP2010523534A (ja) 2010-07-15
BRPI0809996B1 (pt) 2019-09-03
ES2427845T3 (es) 2013-11-04
CN101679434A (zh) 2010-03-24
BRPI0809996A2 (pt) 2014-10-14
RU2009140753A (ru) 2011-05-10
CA2681529C (en) 2015-06-30
WO2008122767A3 (en) 2008-12-31
US20100093769A1 (en) 2010-04-15
CN101679434B (zh) 2013-09-25
HK1139939A1 (en) 2010-09-30
RU2461559C2 (ru) 2012-09-20
MX2009010660A (es) 2010-02-17
JP5466145B2 (ja) 2014-04-09
AU2008235361B2 (en) 2013-02-14
US8592581B2 (en) 2013-11-26
PL2139893T3 (pl) 2013-11-29
WO2008122767A2 (en) 2008-10-16
EP2139893A2 (en) 2010-01-06
BRPI0809996B8 (pt) 2021-05-25
EP2139893B1 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
GB0706632D0 (en) New purine derivatives
ZA201003631B (en) Isoxazolo-pyridine derivatives
IL205753A0 (en) Isoxazolo-pyridazine derivatives
IL202020A0 (en) Spiroindolinone derivatives
IL235555A0 (en) A purine is converted to a pyrimidine
PL2125792T3 (pl) Pochodne puryny jako immunomodulatory
IL210855A (en) Annals of Adenine
ZA201001058B (en) Quinazolinamide derivatives
HRP20140377T1 (en) Pyrimidine derivatives
ZA201000431B (en) Indazolamide derivatives
IL205425A0 (en) Novel pyrimidine derivatives
IL205755A0 (en) Isoxazolo-pyrazine derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
IL208336A0 (en) Pyrisazinone derivatives
ZA201101236B (en) New 2-amidothiadiazole derivatives
IL202667A0 (en) Isoxazole-imidazole derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
IL208548A0 (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
PL2245028T3 (pl) Pochodne 5-aminocyklilometyloksazolidyn-2-onu
EP2133347A4 (en) 1-BIARYLAZETIDINONDERIVATE
IL202463A0 (en) Sulfonyl-quinoline derivatives
IL202159A0 (en) Piperidine-amide derivatives
ZA201002218B (en) Thiadiazinone derivatives
HU0700417D0 (en) Sulfonyl-quinoline derivatives
AP2009005065A0 (en) Sulfonyl-quinoline derivatives

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)